Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | APP | P05067 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569520 | 0.86 | APP (0.56) | MAPTAPPKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL31398833 | 0.85 | HDAC6 (0.56) | MAPTALDH1A1HPGDLMNAHSD17B2 | |
| SCHEMBL26038966 | 0.82 | MAPT (0.51) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL5263932 | 0.80 | APP (0.55) | APPHPGDHSD17B2RPS6KB2 | |
| SCHEMBL5663464 | 0.80 | ACACA (0.60) | MAPTALDH1A1HPGDGAALMNA | |
| SCHEMBL11083765 | 0.79 | HPGD (0.58) | MAPTKDM4EALDH1A1HPGDPTGDR2 | |
| SCHEMBL20772791 | 0.79 | RAB9A (0.47) | MAPTKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL10331951 | 0.78 | APP (0.68) | MAPTAPPKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL28992994 | 0.78 | APP (0.61) | MAPTAPPKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL18885204 | 0.77 | APP (0.66) | MAPTAPPKDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739082-B2 | Thiophene compounds, process for synthesis and use thereof | AHAMMUNE BIOSCIENCES PRIVATE LIMITED (IN) | 2023-08-29 | — | — | US | disclosed |
| US-11739082-B2 | Thiophene compounds, process for synthesis and use thereof | AHAMMUNE BIOSCIENCES PRIVATE LIMITED (IN) | 2023-08-29 | — | — | US | disclosed |
| US-20200255417-A1 | NOVEL THIOPHENE COMPOUNDS, PROCESS FOR SYNTHESIS AND USE THEREOF | AHAMMUNE BIOSCIENCES PRIVATE LIMITED (IN) | 2020-08-13 | — | — | US | disclosed |
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739082-B2 | Thiophene compounds, process for synthesis and use thereof | TPMT, TST, SSB | MAPT 42/4885APP 938/4885KDM4E 2581/4885 |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | TNF, LITAF, MAPK1 | MAPT 1770/4885APP 1773/4885KDM4E 3779/4885 |
| US-20200255417-A1 | NOVEL THIOPHENE COMPOUNDS, PROCESS FOR SYNTHESIS AND USE THEREOF | TPMT, TST, UACA | MAPT 36/4885APP 1154/4885KDM4E 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.